EU Medical Device Committee may play role in regulation of combination products
This article was originally published in SRA
Providing an opinion on the suggested qualification of combination/borderline products is one of the roles that the European Commission is considering for the new statutory Medical Devices Committee (MDC) that it is proposing as part of the recast of the medical device directives.
You may also be interested in...
EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?
Switzerland’s current economic and trading relationship with the UK is based on its MRA with the EU. So, where does this leave the two countries in trading with one another now each of their relationships with the EU are under threat?